| Year |
Citation |
Score |
| 2023 |
Chen P, Khan F, Lin Y, Ali H, Pang L, Dunterman M, Hsu WH, Frenis K, Rowe RG, Wainwright D, McCortney K, Billingham L, Miska J, Horbinski C, Lesniak M. LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression. Research Square. PMID 37886538 DOI: 10.21203/rs.3.rs-3401154/v1 |
0.3 |
|
| 2022 |
Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, ... ... Wainwright DA, et al. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. Journal For Immunotherapy of Cancer. 10. PMID 35902132 DOI: 10.1136/jitc-2022-004935 |
0.304 |
|
| 2022 |
Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunology Research. PMID 35413115 DOI: 10.1158/2326-6066.CIR-21-0559 |
0.323 |
|
| 2021 |
Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger AB. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Frontiers in Immunology. 12: 745893. PMID 34691054 DOI: 10.3389/fimmu.2021.745893 |
0.316 |
|
| 2021 |
Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X, Wu JD, Schipma MJ, Wray B, Griffiths J, Unwin RD, ... ... Wainwright DA, et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34479957 DOI: 10.1158/1078-0432.CCR-21-1392 |
0.322 |
|
| 2020 |
Chuntova P, Chow F, Watchmaker P, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, et al. Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Neuro-Oncology. PMID 33367885 DOI: 10.1093/neuonc/noaa277 |
0.339 |
|
| 2020 |
Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to augment cancer immunotherapy. Current Opinion in Pharmacology. 53: 66-76. PMID 32777746 DOI: 10.1016/J.Coph.2020.07.001 |
0.402 |
|
| 2020 |
Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, Zhang B, Wu JD, Miller SD, Meeks JJ, Lukas RV, Wyatt E, Doglio L, Schiltz GE, McCusker RH, ... Wainwright DA, et al. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Frontiers in Immunology. 11: 1185. PMID 32612606 DOI: 10.3389/Fimmu.2020.01185 |
0.451 |
|
| 2020 |
Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer J, Dixit K, ... ... Wainwright DA, et al. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32546647 DOI: 10.1158/1078-0432.Ccr-19-3874 |
0.402 |
|
| 2020 |
Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. Journal of Hematology & Oncology. 13: 74. PMID 32517713 DOI: 10.1186/S13045-020-00896-0 |
0.357 |
|
| 2019 |
Zhai L, Ladomersky E, Bell A, Dussold C, Cardoza K, Qian J, Lauing KL, Wainwright DA. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods in Enzymology. 629: 235-256. PMID 31727243 DOI: 10.1016/Bs.Mie.2019.07.006 |
0.307 |
|
| 2019 |
Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM. Immunotherapy Against Gliomas: is the Breakthrough Near? Drugs. PMID 31598900 DOI: 10.1007/S40265-019-01203-Z |
0.348 |
|
| 2019 |
Zhang J, Larrocha PS, Zhang B, Wainwright D, Dhar P, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC tumors respond to PD1/PD-L1 blockade therapy. Journal For Immunotherapy of Cancer. 7: 223. PMID 31446896 DOI: 10.1186/S40425-019-0693-Y |
0.348 |
|
| 2019 |
Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, Zhang B. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. PMID 31223045 DOI: 10.2217/Imt-2018-0200 |
0.42 |
|
| 2019 |
Otto-Meyer S, Lumibao J, Kim E, Ladomersky E, Zhai L, Lauing KL, Scholtens DM, Penedo F, Amidei C, Lukas RV, Wainwright DA. The interplay among psychological distress, the immune system, and brain tumor patient outcomes. Current Opinion in Behavioral Sciences. 28: 44-50. PMID 31049368 DOI: 10.1016/J.Cobeha.2019.01.009 |
0.442 |
|
| 2019 |
Ladomersky E, Scholtens DM, Kocherginsky M, Hibler EA, Bartom ET, Otto-Meyer S, Zhai L, Lauing KL, Choi J, Sosman JA, Wu JD, Zhang B, Lukas RV, Wainwright DA. The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Frontiers in Pharmacology. 10: 200. PMID 30971917 DOI: 10.3389/Fphar.2019.00200 |
0.426 |
|
| 2019 |
Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg . (2017). Oncoimmunology. 8: 1548242. PMID 30723577 DOI: 10.1080/2162402X.2018.1548242 |
0.338 |
|
| 2019 |
Rosenberg AJ, Wainwright DA, Fought AJ, Zhai L, Lauing K, Villaflor VM. Abstract 2341: Indoleamine 2,3 dioxegenase 1 (IDO1) and T-cell infiltration in esophageal cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-2341 |
0.317 |
|
| 2019 |
Ladomersky E, Zhai L, Lauing K, Qian J, Bell A, Otto-Meyer S, Dussold C, Lukas R, Wainwright D. IMMU-44. INHIBITING IMMUNOSUPPRESSIVE IDO1 IN ADULTS WITH MALIGNANT GLIOMA – A MOVING TARGET THAT CHANGES WITH TREATMENT, CELL OF ORIGIN, AND AGING Neuro-Oncology. 21: vi128-vi128. DOI: 10.1093/Neuonc/Noz175.536 |
0.434 |
|
| 2019 |
Zhai L, Bell A, Qian J, Ladomersky E, Lauing K, Wainwright D. IMMU-22. TARGETING NON-CANONICAL FUNCTION OF IDO1 IN GLIOBLASTOMA IMMUNOTHERAPY Neuro-Oncology. 21: vi123-vi123. DOI: 10.1093/Neuonc/Noz175.515 |
0.489 |
|
| 2019 |
Ladomersky E, Zhai L, Lauing K, Qian J, Otto-Meyer S, Savoor R, Wainwright D. IMMU-20. ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA Neuro-Oncology. 21: vi123-vi123. DOI: 10.1093/Neuonc/Noz175.513 |
0.357 |
|
| 2019 |
Otto-Meyer S, DeFaccio R, Dussold C, Ladomersky E, Lukas R, Amidei C, Zhai L, Lauing K, Scholtens D, Wainwright D. HOUT-20. TIME-DEPENDENT ANALYSIS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR TREATMENT ON OVERALL SURVIVAL OF PATIENTS WITH GLIOBLASTOMA Neuro-Oncology. 21: vi116-vi116. DOI: 10.1093/Neuonc/Noz175.485 |
0.369 |
|
| 2019 |
Ladomersky E, Zhai L, Lauing K, Qian J, Bell A, Otto-Meyer S, Savoor R, Wainwright D. CBMT-34. MODULATING DIETARY TRYPTOPHAN OR GUT MICROBIOTA LEVELS DOES NOT IMPROVE THE EFFICACY OF COMBINED TREATMENT WITH RADIATION, ANTI-PD-1 mAb, AND AN IDO1 ENZYME INHIBITOR IN A MODEL OF GLIOBLASTOMA Neuro-Oncology. 21: vi40-vi40. DOI: 10.1093/Neuonc/Noz175.156 |
0.369 |
|
| 2019 |
Lenzen A, Lauing KL, Zhai L, Ladomersky E, Raman P, Rathi K, Lulla RR, Hashizume R, Wainwright DA. IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA Neuro-Oncology. 21: ii92-ii93. DOI: 10.1093/Neuonc/Noz036.122 |
0.316 |
|
| 2018 |
Lukas RV, Juhász C, Wainwright DA, James CD, Kennedy E, Stupp R, Lesniak MS. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. Journal of Neuro-Oncology. PMID 30415456 DOI: 10.1007/S11060-018-03013-X |
0.429 |
|
| 2018 |
Kim JW, Kane JR, Panek WK, Young JS, Rashidi A, Yu D, Kanojia D, Hasan T, Miska J, Gómez-Lim MA, Ulasov IV, Balyasnikova IV, Ahmed AU, Wainwright DA, Lesniak MS. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 30027430 DOI: 10.1007/S13311-018-0650-3 |
0.385 |
|
| 2018 |
Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. Oncotarget. 9: 23482-23493. PMID 29805749 DOI: 10.18632/Oncotarget.25235 |
0.324 |
|
| 2018 |
Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang Z, Patel R, ... ... Wainwright DA, et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29500275 DOI: 10.1158/1078-0432.Ccr-17-3573 |
0.428 |
|
| 2018 |
Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, Wu M, Wainwright DA. IDO1 in cancer: a Gemini of immune checkpoints. Cellular & Molecular Immunology. PMID 29375124 DOI: 10.1038/Cmi.2017.143 |
0.409 |
|
| 2018 |
Rosenberg A, Wainwright D, Rademaker A, Galvez C, Genet M, Zhai L, Lauing K, Villaflor VM. Indoleamine 2,3-dioxygenase (IDO1), PD-L1, and overall survival (OS) of patients diagnosed with esophageal cancer. Journal of Clinical Oncology. 36: 50-50. DOI: 10.1200/Jco.2018.36.4_Suppl.50 |
0.347 |
|
| 2018 |
Zhai L, Qian J, Ladomersky E, Lauing K, Scholtens D, Lukas R, Wainwright D. IMMU-41. IDO1 INCREASES Treg RECRUITMENT INDEPENDENT OF TRYPTOPHAN METABOLISM IN A MODEL OF GLIOBLASTOMA Neuro-Oncology. 20: vi130-vi130. DOI: 10.1093/Neuonc/Noy148.544 |
0.367 |
|
| 2018 |
Savoor R, Ladomersky E, Otto-Meyer S, Zhai L, Lauing K, Lenzen A, Lukas R, Wainwright D. IMMU-10. RADIOTHERAPY AND PD-1 BLOCKADE INCREASES TRYPTOPHAN METABOLISM IN BRAIN TUMOR-DRAINING SECONDARY LYMPHOID ORGANS Neuro-Oncology. 20: vi123-vi123. DOI: 10.1093/Neuonc/Noy148.513 |
0.353 |
|
| 2017 |
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. Journal For Immunotherapy of Cancer. 5: 77. PMID 28923102 DOI: 10.1186/S40425-017-0278-6 |
0.326 |
|
| 2017 |
Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV. Management of glioblastoma in elderly patients. Journal of the Neurological Sciences. 380: 250-255. PMID 28870580 DOI: 10.1016/J.Jns.2017.07.048 |
0.328 |
|
| 2017 |
Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder D, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28751450 DOI: 10.1158/1078-0432.Ccr-17-0120 |
0.431 |
|
| 2017 |
Binder DC, Wainwright DA. The Boosting Potential of Bacteria in Cancer Immunotherapy. Trends in Molecular Medicine. PMID 28583420 DOI: 10.1016/J.Molmed.2017.05.008 |
0.369 |
|
| 2017 |
Wainwright DA, Horbinski CM, Hashizume R, James CD. Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28321824 DOI: 10.1007/S13311-017-0523-1 |
0.428 |
|
| 2017 |
Zhai L, Ladomersky E, Dostal CR, Lauing K, Swoap K, Billingham LK, Gritsina G, Wu M, McCusker RH, Binder DC, Wainwright DA. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain, Behavior, and Immunity. PMID 28179106 DOI: 10.1016/J.Bbi.2017.01.022 |
0.49 |
|
| 2017 |
Zhai L, Ladomersky E, Lauing K, Wu M, Genet M, Gritsina G, Gyorffy B, Brastianos P, Binder D, Sosman J, Giles F, James CD, Horbinski CM, Stupp R, Wainwright D. IMMU-66. IDO1 EXPRESSION STRATIFIES PATIENT SURVIVAL AND IS REGULATED BY TUMOR INFILTRATING T CELLS IN HUMAN GLIOBLASTOMA Neuro-Oncology. 19: vi127-vi127. DOI: 10.1093/Neuonc/Nox168.523 |
0.442 |
|
| 2017 |
Lauing K, Lulla R, Lenzen A, Zhai L, Hashizume R, Fangusaro JR, Wainwright D. IMMU-35. TARGETING IDO1 IN HUMAN PEDIATRIC BRAIN CANCER Neuro-Oncology. 19: vi120-vi120. DOI: 10.1093/Neuonc/Nox168.493 |
0.325 |
|
| 2017 |
Lauing KL, Lulla RR, Zhai L, Hashizume R, Fangusaro J, Wainwright DA. IMMU-21. CHARACTERIZING IDO1 AND ITS THERAPEUTIC POTENTIAL IN PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 19: iv32-iv32. DOI: 10.1093/Neuonc/Nox083.131 |
0.393 |
|
| 2016 |
Lenzen A, Zhai L, Lauing KL, Gritsina G, Ladomersky E, Genet M, James CD, Bloch O, Wainwright DA. The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine. Immunotherapy (Los Angeles, Calif.). 2. PMID 27819068 DOI: 10.4172/2471-9552.1000125 |
0.445 |
|
| 2016 |
Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 5: e1196311. PMID 27622066 DOI: 10.1080/2162402X.2016.1196311 |
0.352 |
|
| 2016 |
Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, Han Y, Wu M, Zhang L, Horbinski C, Ahmed AU, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Research. PMID 27530322 DOI: 10.1158/0008-5472.Can-16-0144 |
0.467 |
|
| 2016 |
Ladomersky E, Zhai L, Gritsina G, Genet M, Lauing KL, Wu M, James CD, Wainwright DA. Advanced age negatively impacts survival in an experimental brain tumor model. Neuroscience Letters. PMID 27493076 DOI: 10.1016/J.Neulet.2016.08.002 |
0.459 |
|
| 2016 |
Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology. 5: e1130207. PMID 27471609 DOI: 10.1080/2162402X.2015.1130207 |
0.433 |
|
| 2016 |
Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology. 5: e1082027. PMID 27057463 DOI: 10.1080/2162402X.2015.1082027 |
0.426 |
|
| 2016 |
Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC. Functional cloning of a gp100-reactive T cell receptor from vitiligo patient skin. Pigment Cell & Melanoma Research. PMID 26824221 DOI: 10.1111/Pcmr.12458 |
0.33 |
|
| 2016 |
Ladomersky E, Zhai L, Gritsina G, Lauing KL, Genet M, James CD, Wainwright DA. Abstract B018: A novel IDO1 inhibitor combined with targeted immunotherapy durably increases survival in a mouse model of glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B018 |
0.433 |
|
| 2016 |
Zhai L, Genet M, Ladomersky E, Lauing K, Wu M, Binder D, Kim L, Rich J, Horbinski C, James CD, Sosman JA, Bloch O, Wainwright DA. Abstract A064: IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A064 |
0.328 |
|
| 2016 |
Lauing K, Lulla R, Zhai L, Hashizume R, Fangusaro J, Wainwright DA. Abstract A051: Characterization of IDO1 and TDO2 in pediatric central nervous system tumors Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A051 |
0.453 |
|
| 2016 |
Zhai L, Genet M, Ladomersky E, Lauing K, Wu M, Binder D, Kim L, Rich J, Horbinski C, James CD, Sosman J, Bloch O, Wainwright D. IMST-39. IDO1 IS PROGNOSTIC FOR GLIOBLASTOMA PATIENT SURVIVAL AND CENTRALLY CORRELATES WITH POTENTLY IMMUNOSUPPRESSIVE MEDIATORS Neuro-Oncology. 18: vi95-vi95. DOI: 10.1093/Neuonc/Now212.395 |
0.311 |
|
| 2016 |
Ladomersky E, Zhai L, Gritsina G, Lauing K, Genet M, Bloch O, James CD, Wainwright D. IMST-35. IDO1 AND TARGETED IMMUNOTHERAPY IN A MOUSE GLIOBLASTOMA MODEL Neuro-Oncology. 18: vi94-vi94. DOI: 10.1093/Neuonc/Now212.391 |
0.309 |
|
| 2016 |
Lauing KL, Lulla RR, Hashizume R, Wainwright DA. TB-28IMMUNOSUPPRESSIVE IDO1 AND TDO ARE EXPRESSED IN PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 18: iii173.4-iii173. DOI: 10.1093/Neuonc/Now084.20 |
0.356 |
|
| 2015 |
Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26519060 DOI: 10.1158/1078-0432.Ccr-15-0420 |
0.385 |
|
| 2015 |
Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas MK, Rademaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT, Bloch O, Wainwright DA. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 26279502 DOI: 10.1016/J.Jocn.2015.06.018 |
0.393 |
|
| 2015 |
Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias A, Zhang L, Qiao J, Lesniak MS. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. Journal of Immunology (Baltimore, Md. : 1950). 195: 367-76. PMID 26026061 DOI: 10.4049/Jimmunol.1401607 |
0.429 |
|
| 2015 |
Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, Wainwright DA. The role of IDO in brain tumor immunotherapy. Journal of Neuro-Oncology. 123: 395-403. PMID 25519303 DOI: 10.1007/S11060-014-1687-8 |
0.465 |
|
| 2015 |
Chang AL, Miska J, Wainwright DA, Dey M, Qiao J, Pytel P, Han Y, Zhang L, Balyasnikova IV, Ahmed AU, Lesniak MS. Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P72 |
0.448 |
|
| 2015 |
Zhai L, Lauing K, Qian J, Gritsina G, Dostal C, McCusker R, Wainwright D. IMPS-43IDO1 DOES NOT FUNCTION AS A TRYPTOPHAN CATABOLIC ENZYME IN MALIGNANT GLIOMA Neuro-Oncology. 17: v122.3-v122. DOI: 10.1093/Neuonc/Nov217.42 |
0.411 |
|
| 2015 |
Wainwright D. Imps-39Ido1: More Than Just An Enzyme In Malignant Glioma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov217.38 |
0.456 |
|
| 2014 |
Cheng Y, Dai Q, Morshed RA, Fan X, Wegscheid ML, Wainwright DA, Han Y, Zhang L, Auffinger B, Tobias AL, Rincón E, Thaci B, Ahmed AU, Warnke PC, He C, et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small (Weinheim An Der Bergstrasse, Germany). 10: 5137-50. PMID 25104165 DOI: 10.1002/Smll.201400654 |
0.35 |
|
| 2014 |
Wainwright DA, Lesniak MS. Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma. Oncoimmunology. 3: e28927. PMID 25057450 DOI: 10.4161/Onci.28927 |
0.463 |
|
| 2014 |
Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y, Lesniak MS. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5290-301. PMID 24691018 DOI: 10.1158/1078-0432.Ccr-14-0514 |
0.478 |
|
| 2014 |
Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Therapy. 21: 38-44. PMID 24434573 DOI: 10.1038/Cgt.2013.81 |
0.372 |
|
| 2014 |
Dey M, Chang AL, Wainwright DA, Ahmed AU, Han Y, Balyasnikova IV, Lesniak MS. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. Journal of Neuroimmunology. 266: 33-42. PMID 24268287 DOI: 10.1016/J.Jneuroim.2013.10.012 |
0.458 |
|
| 2014 |
Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML, Auffinger B, Wainwright DA, Lesniak MS, Tirrell MV. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 35: 1249-56. PMID 24211079 DOI: 10.1016/J.Biomaterials.2013.10.064 |
0.357 |
|
| 2014 |
Moon K, Wainwright DA, Balyasnikova IV, Kim CK, Ko YS, Kim KK, Lesniak MS. Abstract LB-64: Immune modulatory effects of mesenchymal stem cells on regulatory T cells in mouse glioma model Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-64 |
0.421 |
|
| 2014 |
Chang AL, Wainwright DA, Dey M, Han Y, Lesniak MS. Abstract 1091: CCR4+ regulatory T cells progressively accumulate in the presence of leukocyte-derived CCL22/CCL17 in an experimental model of glioblastoma multiforme Cancer Research. 74: 1091-1091. DOI: 10.1158/1538-7445.Am2014-1091 |
0.474 |
|
| 2014 |
Dey M, Chang A, Wainwright D, Ahmed A, Han Y, Lesniak M. IT-07 * COMPARATIVE EVALUATION OF pDCs AND mDCs FOR DENDRITIC CELL BASED VACCINE STRATEGY FOR MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.6 |
0.427 |
|
| 2013 |
Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Frontiers in Immunology. 4: 116. PMID 23720663 DOI: 10.3389/Fimmu.2013.00116 |
0.47 |
|
| 2013 |
Chang A, Wainwright D, Dey M, Han Y, Lesniak M. Ir-003. Ccr4+ Regulatory T Cells Accumulate Within The Brain Tumor In An Experimental Model Of Gbm Neuro-Oncology. 15. DOI: 10.1093/Neuonc/Not177.257 |
0.433 |
|
| 2012 |
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6110-21. PMID 22932670 DOI: 10.1158/1078-0432.Ccr-12-2130 |
0.494 |
|
| 2012 |
Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B, Lesniak MS. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. The Journal of Biological Chemistry. 287: 30215-27. PMID 22778273 DOI: 10.1074/Jbc.M112.370015 |
0.347 |
|
| 2012 |
Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. Recent developments on immunotherapy for brain cancer. Expert Opinion On Emerging Drugs. 17: 181-202. PMID 22533851 DOI: 10.1517/14728214.2012.679929 |
0.466 |
|
| 2012 |
Xin J, Mesnard NA, Beahrs T, Wainwright DA, Serpe CJ, Alexander TD, Sanders VM, Jones KJ. CD4+ T cell-mediated neuroprotection is independent of T cell-derived BDNF in a mouse facial nerve axotomy model. Brain, Behavior, and Immunity. 26: 886-90. PMID 22426430 DOI: 10.1016/J.Bbi.2012.02.011 |
0.345 |
|
| 2012 |
Wainwright D, Balyasnikova I, Ahmed A, Auffinger B, Han Y, Lesniak M. 46. Upregulation of indoleamine 2,3-dioxygenase in brain tumors is associated with decreased survival through a T cell-dependent mechanism Brain, Behavior, and Immunity. 26: S13. DOI: 10.1016/J.Bbi.2012.07.070 |
0.487 |
|
| 2011 |
Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncology. 13: 1308-23. PMID 21908444 DOI: 10.1093/Neuonc/Nor134 |
0.477 |
|
| 2011 |
Wainwright DA, Balyasnikova IV, Han Y, Lesniak MS. The expression of BST2 in human and experimental mouse brain tumors. Experimental and Molecular Pathology. 91: 440-6. PMID 21565182 DOI: 10.1016/J.Yexmp.2011.04.012 |
0.464 |
|
| 2011 |
Wainwright D, Sengupta S, Han Y, Lesniak M. 156. Thymus-derived rather than tumor-induced regulatory T cells predominate in human and experimental mouse brain tumors Brain, Behavior, and Immunity. 25: S224. DOI: 10.1016/J.Bbi.2011.07.159 |
0.442 |
|
| 2010 |
Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. Plos One. 5: e15390. PMID 21060663 DOI: 10.1371/Journal.Pone.0015390 |
0.381 |
|
| 2010 |
Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia (New York, N.Y.). 12: 837-47. PMID 20927322 DOI: 10.1593/Neo.10662 |
0.449 |
|
| 2010 |
Wainwright DA, Xin J, Mesnard NA, Sanders VM, Jones KJ. Toll-like receptor 2 and facial motoneuron survival after facial nerve axotomy. Neuroscience Letters. 471: 10-4. PMID 20056129 DOI: 10.1016/J.Neulet.2009.12.076 |
0.316 |
|
| 2009 |
Wainwright DA, Xin J, Mesnard NA, Beahrs TR, Politis CM, Sanders VM, Jones KJ. Exacerbation of facial motoneuron loss after facial nerve axotomy in CCR3-deficient mice. Asn Neuro. 1: e00024. PMID 19922414 DOI: 10.1042/An20090017 |
0.319 |
|
| 2008 |
Xin J, Wainwright DA, Serpe CJ, Sanders VM, Jones KJ. Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy. Brain, Behavior, and Immunity. 22: 528-37. PMID 18024079 DOI: 10.1016/J.Bbi.2007.10.006 |
0.34 |
|
| Show low-probability matches. |